234 related articles for article (PubMed ID: 34231197)
1. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Cicali EJ; Elchynski AL; Cook KJ; Houder JT; Thomas CD; Smith DM; Elsey A; Johnson JA; Cavallari LH; Wiisanen K
Clin Pharmacol Ther; 2021 Sep; 110(3):677-687. PubMed ID: 34231197
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
3. Addressing phenoconversion: the Achilles' heel of personalized medicine.
Shah RR; Smith RL
Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
[TBL] [Abstract][Full Text] [Related]
4. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
5. The importance of phenoconversion when using the
Cicali EJ; Wiisanen K
Pharmacogenomics; 2022 Sep; 23(14):749-752. PubMed ID: 36102178
[TBL] [Abstract][Full Text] [Related]
6. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
[TBL] [Abstract][Full Text] [Related]
7. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Drevin G; Picard N; Jousset N; Briet M; Abbara C
Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
Bahar MA; Setiawan D; Hak E; Wilffert B
Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
[TBL] [Abstract][Full Text] [Related]
9. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of pharmacogenetics in pain management.
Smith DM; Weitzel KW; Cavallari LH; Elsey AR; Schmidt SO
Per Med; 2018 Mar; 15(2):117-126. PubMed ID: 29714124
[TBL] [Abstract][Full Text] [Related]
13. Prediction of CYP2D6 phenotype from genotype across world populations.
Gaedigk A; Sangkuhl K; Whirl-Carrillo M; Klein T; Leeder JS
Genet Med; 2017 Jan; 19(1):69-76. PubMed ID: 27388693
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
15. Keeping pace with
Brown KE; Staples JW; Woodahl EL
Pharmacogenomics; 2022 Mar; 23(4):255-262. PubMed ID: 35083931
[TBL] [Abstract][Full Text] [Related]
16. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
Cicali EJ; Weitzel KW; Elsey AR; Orlando FA; Vinson M; Mosley S; Smith DM; Davis R; Drum L; Estores D; Franciosi JP; Hagen MG; Jerkins GJ; Mercado ES; Nainaparampil J; Padron A; Rosenberg EI; Wright A; Schmidt SO; Mathews CA; Cavallari LH; Johnson JA
Genet Med; 2019 Oct; 21(10):2264-2274. PubMed ID: 30926959
[TBL] [Abstract][Full Text] [Related]
17. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
Berm E; Kok R; Hak E; Wilffert B
Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
[No Abstract] [Full Text] [Related]
18. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
Deneer VH; van Schaik RH
Methods Mol Biol; 2013; 1015():345-54. PubMed ID: 23824868
[TBL] [Abstract][Full Text] [Related]
19. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Cavallari LH; Van Driest SL; Prows CA; Bishop JR; Limdi NA; Pratt VM; Ramsey LB; Smith DM; Tuteja S; Duong BQ; Hicks JK; Lee JC; Obeng AO; Beitelshees AL; Bell GC; Blake K; Crona DJ; Dressler L; Gregg RA; Hines LJ; Scott SA; Shelton RC; Weitzel KW; Johnson JA; Peterson JF; Empey PE; Skaar TC;
Genet Med; 2019 Oct; 21(10):2255-2263. PubMed ID: 30894703
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics in psychiatry - the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing.
Mostafa S; Polasek TM; Bousman CA; Müeller DJ; Sheffield LJ; Rembach J; Kirkpatrick CM
Pharmacogenomics; 2022 Oct; 23(15):857-867. PubMed ID: 36169629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]